Why VolitionRx Limited’s (VNRX) Stock Is Up 5.28%
As of Monday, November 03, VolitionRx Limited’s VNRX share price has surged by 5.28%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Commentary & Analysis
Why VolitionRx Limited’s (VNRX) Stock Is Up 6.09%
As of Thursday, October 30, VolitionRx Limited’s VNRX share price has surged by 6.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why VolitionRx Limited’s (VNRX) Stock Is Down 21.25%
As of Friday, October 10, VolitionRx Limited’s VNRX share price has dipped by 21.25%, which has investors questioning if this is right time to buy.Omar Beirat
Why VolitionRx Limited’s (VNRX) Stock Is Down 5.35%
As of Thursday, October 09, VolitionRx Limited’s VNRX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Jenna Brashear
Why VolitionRx Limited’s (VNRX) Stock Is Up 5.10%
As of Friday, October 03, VolitionRx Limited’s VNRX share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.6 | $413.8 | 2% |
|
| Shares Out (Mil) | 9.2 | 40.6 | 20% |
|
| Institutional Ownership | 85.4% | 83.6% | 53% |
|
| Float (Mil) | 12.5 | 34.7 | 22% |
|
| Beta | 1.17 | 0.87 | 69% |
|
| Avg Daily Volume (000s) | 1,220 | 271 | 74% |
|
| Price Change (52-week) |
(97.9%) | 65.5% | 2% |
|
| Growth | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (2.8%) | (5.5%) | 36% |
|
| EPS (5yr) | 13.4% | 10.7% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.8%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.310) | ($2.000) | ($0.850) | |
| Month Ago EPS | ($0.310) | ($2.000) | ($0.850) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.580) | ($2.620) | ($1.150) | |
| Year/Year Chg | (63.5%) | (54.3%) | (91.3%) | |
| Financials | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $128 | 4% |
|
| Net Income (TTM) (Mil) | ($26) | ($10) | 22% |
|
| EPS (TTM) | ($3.804) | ($0.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($2) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 44% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $27 | 26% |
|
| Enterprise Value (Q1) (Mil) | $10 | $409 | 8% |
|
| Valuation | VNRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.47 | na |
|
| P/E | na | 28.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 59.3% | 96% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (301.5%) | (12.2%) | 1% |
|
| ROE | 80.1% | (10.8%) | 95% |
|
| Liabilities to Assets | 504.0% | 47.2% | 100% |
|
| F-Score | 3 | 4 | 18% |
|
VolitionRx Limited did not pass any screens on 10/28/2026.
